throbber
Neuro
`endocrinology
`
`Neuroendocrinology 2004;80(supp| 1):79—84
`DOI: 10.1159/000080747
`
`Chemotherapy for Gastro-Enteropancreatic
`Endocrine Tumours
`
`Dermot O'Toole Olivia Hentic Olivier Corcos Philippe Ruszniewski
`
`Service de Gastroentérologie, Hopital Beaujon, Clichy, France
`
`Key Words
`Gastro-enteropancreatic endocrine tumours -
`Chemotherapy - We||—differentiated tumours - Poorly
`differentiated tumours
`
`Abstract
`
`Despite similar histological and morphological aspects,
`gastro-enteropancreatic (GEP) endocrine tumours repre-
`sent a heterogeneous group of tumours with varying
`clinical expression depending on tumour type (function-
`al or not), origin and extension, but also on histological
`differentiation and proliferative capacity. The natural his-
`tory of we||—differentiated tumours is often favourable
`without treatment and GEP endocrine tumours may
`remain indolent for many years. Chemotherapy may
`however be indicated in the presence of symptomatic
`non-progressive disease (progression evaluated over 3-
`6 months). In contrast, poorly differentiated GEP endo-
`crine tumours are frequently aggressive and early treat-
`ment is required. Accurate staging is mandatory and
`where surgery is possible (even in the event of limited
`metastatic disease), this option should be re-evaluated in
`a multidisciplinary approach. Approximately 2/3 of ma-
`lignant GEP tumours are metastatic at discovery and sur-
`gery is possible in a minority of patients; therefore, che-
`motherapy, with/without other strategies (e.g. local abla-
`
`tion), is frequently indicated in patients with symptomat-
`ic, bulky or progressive disease. For well-differentiated
`pancreatic tumours, the reference association is Adria-
`mycin with streptozotocin yielding objective responses
`(OR) in 40-60% of patients. Prolonged treatment is lim-
`ited due to potential cardiotoxicity of Adriamycin and
`standard 2nd—|ine regimens are not of proven efficacy;
`thus, other treatment modalities are usually additionally
`required (e.g. chemo—embo|isation). A significant OR
`may render a small number of patients secondarily am-
`enable to surgery. Published series evaluating chemo-
`therapy for midgut endocrine tumours are outdated and
`disappointing. Objective response rates with combined
`associations (including either 5-fluorouracil and/or strep-
`tozotocin) rarely exceed 20% and where possible, che-
`mo-embolisation for hepatic metastases combined with
`somatostatin analogues (i interferon) should be pre-
`ferred. Poorly differentiated GEP tumours are generally
`aggressive tumours with metastases at diagnosis and
`tend to progress rapidly. Surgery is rarely possible and
`ineffective even in locally advanced disease due to a high
`risk of recurrence. Chemotherapy, using cisplatin and
`etoposide,
`is the reference treatment and frequently
`yields OR rates >50%. However, despite being chemo-
`sensitive, disease control is limited (8-10 months). Over-
`all, advances in therapeutic chemotherapeutic options
`are required in the management of all types of advanced
`
`E R
`Fax +41 61 306 12 34
`E-Mail k1uger@ka.tger. ch
`www.karger.com
`
`© 2004 S. Karger AG, Basel
`0028-3835/04/0807—0079$21.00/0
`
`Accessible online at:
`www.karger.comlnen
`
`D. O’Toole
`Service de Gastroentérologie, Hépital Beaujon
`100, boulevard du Général Leclerc
`FR—921 10 Clichy Cedex (France)
`Tel. +33 1 40 87 57 33, Fax +33 1 42 70 37 84, E-Mail dermot.otoole@bjn.ap-hop-paris.fr
`
`
`
`West-Ward Pharm.
`Exhibit 1063
`Page 001
`
`

`

`GEP endocrine tumours and evaluation of new drugs
`(e.g. irinotecan) and combination strategies (chemother-
`apy with local ablative therapies) are required in the
`futu re.
`
`Copyright© 2004 S. KargerAG, Basel
`
`Introduction
`
`Endocrine tumours of gastro-enteropancreatic (GEP)
`origin are a heterogeneous group of tumours of variable
`prognosis. The natural history varies from a frequently
`indolent course for tumours which are well differentiated
`
`to a much more aggressive form with poorly differen-
`tiated tumours. The principles of management of patients
`with GEP endocrine tumours depend on a number of fac-
`tors requiring a multidisciplinary approach. Recent ad-
`vances in surgery imply that patients even with bilobar
`liver metastases may be deemed suitable to surgery using
`two-stage hepatectomies [1, 2] and therefore prior to con-
`sidering patients for chemotherapy, a surgical option
`should always be reconsidered. Nonetheless, surgery is
`rarely possible in patients with metastatic disease and oth-
`er approaches are therefore necessary.
`As opposed to treatment decisions for other solid
`tumours of the digestive tract, ‘wait-and-see’ strategies
`can often be adopted in patients with GEP tumours.
`The slow-growing nature of well-differentiated tumours
`means that chemotherapy and other treatment strategies
`should be reserved for patients with progressive disease.
`Indeed, to date interpretation of data on treatment of
`patients with GEP tumours has been hampered by the
`lack of evidence for progressive disease in a number of
`studies. Documented progression (on either solid clinical
`grounds or a 2 25 °/o increase in targeted lesions or appear-
`ance of a new disease in patients with non-symptomatic
`disease) should be based on accurate and comparable
`evaluation of clinical, biological and morphological data
`at least at 3-monthly intervals. Given that response to
`cytotoxic agents in patients with GEP tumours may be
`short-lived, determining the correct moment to com-
`mence treatment is often difficult. Early treatment at the
`outset is, on the contrary, usually necessary for patients
`with aggressive well-differentiated tumours and for those
`with poorly differentiated lesions whose natural history
`mirrors that of small cell lung cancer. Another consider-
`ation in commencing treatment at the moment of diagno-
`sis is the presence of bulky disease, especially the presence
`of extensive liver metastases (usually >70%).
`
`Until now, the type of chemotherapy has been largely
`based on the site of origin of the primary tumour and on
`the histological differentiation. Endocrine tumours of the
`duodenum or pancreas, whether functional or not, are
`considered for cytotoxic regimens, which greatly differ
`from those of midgut origin. In addition, given that
`tumour differentiation also dictates response to individu-
`al cytotoxic protocols, correct histological classification
`should be applied using strict WHO criteria [3]. Accurate
`histological classification is not always easy as interob-
`server differences among pathologists are not uncommon
`and guidelines to increase uniformity are required. The
`importance of accurate histology cannot be underesti-
`mated and in cases where doubt exists, slides should be
`sent for an expert opinion. The recent use of the prolifera-
`tion index Ki-67 has been helpful in distinguishing certain
`tumours and guiding treatment regimens; this marker is
`invariably high (>15%) in poorly differentiated lesions;
`however, cases with a histological architecture resembling
`well-differentiated tumours and moderately elevated Ki-
`67 (between 2 and 15% or ‘borderline tumours’) [3] may
`be problematic when it comes to choosing chemotherapy.
`The appraisal of proliferation indices on treatment out-
`comes is requisite in future protocols.
`
`Chemotherapy for Well-Differentiated GEP
`Tumours of the Pancreas or Duodenum
`
`Apart from insulinomas, other GEP tumours from the
`pancreas or duodenum are frequently associated with
`metastatic disease and curative surgical options are rarely
`possible (<25 %) [4]. Thus, cytotoxic therapy is a frequent-
`ly posed question in these patients. Single-agent chemo-
`therapy with streptozotocin yielded tumour response
`rates of between 36 and 42% [5, 6]; however, these early
`studies can be criticized with respect to the crude methods
`of interpreting morphological responses. Other monother-
`apies including chlorozotocin, doxorubicin, 5-fluorouracil
`(5-FU) [7] or dacarbazine [5, 8] have been used but criti-
`cised either due to the high toxicity rate or lack of objec-
`tive response. Such strategies have been universally re-
`placed by combination chemotherapy protocols. As seen
`in table 1, many associations have been used with strepto-
`zotocin, 5-FU and anthracyclines forming the cornerstone
`of the regimens tested. The results by Moertel et al. [9] in
`1992 using streptozotocin and doxorubicin have not been
`bettered to date, with a 69% objective response rate and a
`median survival of 26 months; this compared to a 45%
`objective response rate for 5-FU and streptozotocin. The
`
`80
`
`Neuroendocrinology 2004;80(suppl 1):79—84
`
`O’Toole/Hentic/Corcos/Ruszniewski
`
`
`
`West-Ward Pharm.
`Exhibit 1063
`Page 002
`
`

`

`Table 1 . Combination chemotherapy for
`well-differentiated endocrine tumours of
`the pancreas and duodenum
`
`
`
`Moertel et a1. [10]
`
`Moertel et al. [9]
`
`Eriksson et al. [13]
`Bukowski et al. [14]
`Rivera and Ajani [1 1]
`Cheng and Saltz [15]
`Bajetta et al. [37]
`
`III
`
`III
`
`II
`II
`II
`II
`II
`
`STZ
`STZ + 5-FU
`DOX + STZ
`5-FU + STZ
`DOX + STZ
`CLZ +5-FU
`STZ +5-FU + DOX
`DOX + STZ
`5-FU + EPI + DTIC
`
`42
`42
`36
`33
`25
`44
`12
`16
`15
`
`36
`6 3
`69
`45
`36
`36
`55
`6
`27
`
`17
`17
`18
`14
`22
`1 1
`15
`18
`10
`
`17
`26
`26
`18
`—
`—
`21
`—
`—
`
`STZ = Streptozotocin; DOX = doxorubicin; CLZ = chlorozotocin; EPI = epirubicin;
`DTIC = dacarbazine.
`
`same group had previously obtained better results with
`5-FU/streptozotocin in a phase III trial comparison to
`monotherapy with streptozotocin [10]. While no group has
`managed to achieve the same response rates, objective
`response rates of between 36 and 55% have been estab-
`lished using streptozotocin/doxorubicin [1 1-14] with the
`exception of Cheng et al. [15] who reported a 6% response
`rate in a group of 16 patients. Cheng et al. [15] in their
`article questioned the reliability of the earlier studies by
`Moertel et al. [9] especially concerning methods of mea-
`suring responses. However, a recent report by Delaunoit et
`al. [12] in 45 patients found a 36% overall response rate
`using well-defined criteria for recruitment and evaluation;
`in addition, 2- and 3-year overall survival rates were 50
`and 24%, respectively. Such discrepancies are difficult to
`explain; however, while the 69% response rates by Moer-
`tel’s group have not been re-achieved, a combination of
`streptozotocin with either doxorubicin or 5-FU in the
`treatment of advanced GEP tumours of the pancreas or
`duodenum is supported by recent data [1 1-14]. Nonethe-
`less, despite being the standard treatment, newer agents
`need to be tested in appropriate phase II and III trials.
`The cumulative cardiotoxicity of doxorubicin, quick-
`ly attained following the standard Moertel regimen (the
`prevalence of cardiomyopathy increases significantly
`when patients are given doses of doxorubicin >550 mg/
`m2 [l6]) means that strategies with 5-FU should be con-
`sidered either at the outset or following maximal treat-
`ment with anthracyclines. The use of agents with less car-
`diotoxicity may also be worthwhile (e.g. epiadriamycin
`and liposomal formulations [17, 18]); however, appraisal
`of both efficacy and toxicity is required prior to universal
`approval for this indication. Careful monitoring of renal
`
`function with 24-hour proteinuria prior to each cycle
`administration of streptozotocin is advised to avoid per-
`manent renal damage. Nausea and vomiting are usually
`not problematic provided adequate antiemetics are sys-
`tematically administered (we combine 5-HT3 inhibitors
`with corticosteroids on a routine basis unless otherwise
`
`contra-indicated).
`
`Well-Differentiated GEP Tumours of Midgut
`Origin
`
`Similar to well-differentiated GEP tumours of the pan-
`creas and duodenum, in GEP tumours of midgut origin,
`single-agent regimens have been largely disappointing
`with objective response rates <25% and response dura-
`tions rarely exceeding 3 months [5]. In 1979, Moertel and
`Hanley [19] combined 5-FU with streptozotocin in mid-
`gut carcinoids yielding a response rate of 33%. Studies
`using the same combination since then have failed to
`reproduce these results (table 2) [20—23]. Therefore, other
`combinations have also been examined and apart from a
`40% objective response rate for patients with midgut car-
`cinoids observed using doxorubicin and streptozotocin in
`a phase II study [24], no other reliable cytotoxic regimen
`has been found for patients with advanced or metastatic
`disease of midgut origin. The association of cytotoxics
`with interferon has also been investigated with largely
`poor outcome success apart from one study by Andreyev
`et al. [25] who demonstrated a 47% objective response
`using a combination of interferon with continuous infu-
`sion of 5-FU; response duration lasted 21 months. The
`excellent, and reproducible, results obtained with chemo-
`
`Chemotherapy for Gastro-Enteropancreatic
`Endocrine Tumours
`
`Neuroendocrinology 2004;80(suppl 1):79—84
`
`81
`
`Pharm.
`ibit 1063
`
`age 003
`
`West-Ward Pharm.
`Exhibit 1063
`Page 003
`
`

`

`Table 2. Combination chemotherapy for
`well-differentiated GEP tumours of midgut
`origin
`
`
`
`Moertel and Hanley [19]
`
`Engstrom et al. [20]
`
`Moertel et al. [21]
`
`Frame et al. [24]
`Moertel et al. [22]
`Di Bartolomeo et al. [23]
`
`III
`
`III
`
`III
`
`II
`II
`II
`
`5-FU + cyclophosphamide
`5-FU + STZ
`5-FU + STZ
`DOX
`MTX + cyclophospahmide
`STZ + cyclophosphamide
`DOX + STZ
`VP 1 6 + cisplatin
`5-FU + DOX + DTIC
`
`47
`422
`80
`81
`16
`14
`33
`13
`20
`
`26
`33
`22
`21
`0
`0
`40
`0
`10
`
`—
`—
`15
`11
`—
`—
`11
`—
`5
`
`STZ = Streptozotocin; DOX = doxorubicin; DTIC = dacarbazine.
`
`Table 3. Combination chemotherapy for
`poorly differentiated GEP tumours
`
`Moertel et al. [22]
`Seitz et al. [28]
`Mitry et al. [29]
`
`etoposide + cisplatin
`etoposide + cisplatin
`etoposide + cisplatin
`
`18
`11
`41
`
`67
`54
`42
`
`8
`—
`9
`
`19
`-1
`15
`
`1
`
`65% survival at 1 year.
`
`embolisation in patients with hepatic metastases and car-
`cinoid syndrome (tumour response rates of approximate-
`ly 40-50% and excellent control of symptoms) [26] argue
`for its use in such patients with liver metastases. In
`patients with extensive disease outside of the liver (e.g.
`carcinomatosis or bony metastases), current treatment
`strategies are wanting and novel approaches using peptide
`receptor radionuclide therapy [27] have appeared more
`seductive to date than endless trials with largely ineffec-
`tive cytotoxics. Investigation of newer treatment options
`such as targeted molecular approaches may also prove of
`value in these patients.
`
`Chemotherapy of Poorly Differentiated GEP
`Tumours
`
`Standard treatment in patients with advanced poorly
`differentiated GEP tumours has largely been based on
`protocols containing etoposide and cisplatin (table 3).
`While tumour response rates are often good (42—65%),
`duration of response rarely exceeds 10 months and me-
`
`dian survival is in the order of 15 months [22, 28, 29].
`Newer options are required for the treatment of these
`patients.
`
`Other Indications for Chemotherapy in GEP
`Tumours (Adjuvant or Neo-Adjuvant)
`
`To date, there have been no data to support the system-
`atic use of chemotherapy in an adjuvant setting. Some
`units have adopted policies of 4 cycles of adjuvant chemo-
`therapy following resection of hepatic metastases (includ-
`ing some unpublished personal observations); however,
`evaluation of such treatment requires a randomized study
`comparing adjuvant treatment to surgery alone. Adjuvant
`chemotherapy is frequently employed following hepatic
`transplantation for metastases of digestive GEP tumours
`[2, 30]; however, its indication has not been evaluated and
`such a study would prove very difficult given the rarity of
`transplantation in this setting. While chemotherapy in a
`neo-adjuvant setting has not been formally evaluated in
`patients with digestive GEP tumours, we and others have
`
`82
`
`Neuroendocrinology 2004;80(suppl 1):79—84
`
`O’Toole/Hentic/Corcos/Ruszniewski
`
`Pharm.
`ibit 1063
`
`age 004
`
`West-Ward Pharm.
`Exhibit 1063
`Page 004
`
`

`

`performed resection of both primary tumours and liver
`metastases following excellent chemotherapy-induced ob-
`jective responses (personal experience). A surgical ap-
`proach should be discussed where chemotherapy or other
`strategies render patients (event with metastatic disease)
`operable.
`
`Perspectives
`
`Agents showing promising results in the setting of oth-
`er solid gastro-intestinal tumours have been applied to
`patients with GEP tumours. Irinotecan, in a single-agent
`form, has recently been found to be inactive in patients
`with carcinoid syndrome [31]. Paclitaxel in high dose
`(250 mg/m2) was also found to be disappointing with an
`8% response rate and significant haematological toxicity
`[32]. A search for expression of tyrosine kinase receptors,
`namely c-kit, has also been performed in GEP tumours.
`Fjéillskog et al. [33] found 35 of 38 tissue specimens (92%)
`from GEP tumours to express c-kit on tumour cells. How-
`ever, a phase II trial using the PDGF-R inhibitor imatinib
`(found to be revolutionary in gastro-intestinal stromal
`
`tumours) in 21 patients with advanced GEP tumours
`demonstrated only weak biological activity with a partial
`response in only 1 patient; 8 patients with progressive dis-
`ease at study entry were progression-free at 3 months [34].
`This might be explained by the mixed results for c-kit
`staining found in GEP tumours as highlighted by Theo-
`dossiou et al. [35] who found only 9% positive weak stain-
`ing in 21 patients with metastatic GEP tumours. Interest-
`ingly,
`inhibitors of epidermal growth factor receptors
`have shown antiproliferative activity in in vitro GEP
`tumour models. Hopfner et al. [36] demonstrated a time-
`and dose-dependant growth inhibition of the insulinoma
`cell line as well as in pancreatic BON cells and in gut
`SCT-1 cells. Discerning antiproliferative mechanisms
`should provide more efficacious chemotherapeutics and
`molecular arsenals for the targeting of these tumours. One
`such approach which should work stems from the vascu-
`larity of such tumours allowing the intriguing prospect of
`developing anti-angiogenic agents (e.g. anti-VEGF factors
`and inhibitors of EGF-R) and while industry-driven re-
`search is mainly focused on other digestive solid tumours,
`advances in the latter area will no doubt aid in our
`
`approach to GEP tumours.
`
`References
`
`1 Kianmanesh R, Farges O, Abdalla EK, Sauva-
`net A, Ruszniewski P, Belghiti J: Right portal
`vein ligation: A new planned two-step a1l-surgi-
`cal approach for complete resection of primary
`gastrointestinal tumors with multiple bilateral
`liver metastases. J Am Coll Surg 2003;197:
`164-170.
`2 O’Toole D, Kianmanesh R, Farges O, Rusz-
`niewski P: Treatment of pancreatic-duodenal
`endocrine tumors. Rev Prat 2002;52:1546—
`1553.
`3 Solcia E, Kliippel G, Sobin LH: Histological
`typing ofendocrine tumours; in Solcia E, Kl6p-
`pel G, Sobin LH (eds): Histological Typing of
`Endocrine Tumours (International Classifica-
`tion of Tumours), ed 2. New York, Springer,
`2000.
`4 McEntee GP, Nagomey DM, Kvols LK, Moer-
`tel CG, Grant CS: Cytoreductive hepatic sur-
`gery for neuroendocrine tumors. Surgery 1990;
`10821091-1096.
`5 Moertel CG: Karnofsky memorial lecture. An
`odyssey in the land of small tumors. J Clin
`Oncol l987;5:1502-1522.
`6 Broder LE, Carter SK: Pancreatic islet cell car-
`cinoma. 2. Results of therapy with streptozoto-
`cin in 52 patients. Ann Intern Med 1973;79:
`108-118.
`
`7 Moertel CG, Lavin PT, Hahn RG: Phase II
`trial of doxorubicin therapy for advanced islet
`cell carcinoma. Cancer Treat Rep 1982;66:
`1567-1569.
`8 Altimari AF, Badrinath K, Reisel HJ, Prinz
`RA: DTIC therapy in patients with malignant
`intra-abdominal neuroendocrine tumors. Sur-
`gery 1987;102:1009-1017.
`9 Moertel CG, Lefkopoulo M, Lipsitz S, Hahn
`RG, Klaassen D: Streptozocin-doxorubicin,
`streptozocin-fluorouracil or chlorozotocin in
`the treatment of advanced islet-cell carcinoma.
`N Engl J Med 1992;326:519-523.
`10 Moertel CG, Hanley JA, Johnson LA: Strepto-
`zocin alone compared with streptozocin plus
`fluorouracil in the treatment of advanced islet-
`cell carcinoma. NEnglJ Med 1980;303:1189-
`1 194.
`11 Rivera E, AjaniJA: Doxorubicin, streptozocin,
`and 5-fluorouracil chemotherapy for patients
`with metastatic islet-cell carcinoma. Am J Clin
`Oncol1998;21:36—38.
`12 Delaunoit T, Ducreux M, Boige V, Dromain C,
`Sabourin JC, Duvillard P, Schlumberger M, de
`Baere T, Rougier P, Ruflie P, et al: The doxoru-
`bicin-streptozotocin combination for the treat-
`ment of advanced well-differentiated pancreat-
`ic endocrine carcinoma; a judicious option?
`Eur J Cancer 2004;40:515-520.
`
`13 Eriksson B, Skogseid B, Lundqvist G, Wide L,
`Wflander E, Oberg K: Medical treatment and
`long-terrn survival in a prospective study of 84
`patients with endocrine pancreatic tumors.
`Cancer 1990;65:1883—1890.
`14 Bukowski RM, Tangen C, Lee R, Macdonald
`JS, Einstein AB Jr, Peterson R, Fleming TR:
`Phase II trial of chlorozotocin and fluorouracil
`in islet cell carcinoma: A Southwest Oncology
`Group study. J Clin Oncol 1992;l0:19l4—
`1918.
`15 Cheng PN, Saltz LB: Failure to confirm major
`objective antitumor activity for streptozocin
`and doxorubicin in the treatment of patients
`with advanced islet cell carcinoma. Cancer
`1999;86:944-948.
`16 Yeh ET, Tong AT, Lenihan DJ, Yusuf SW,
`Swafford J, Champion C, Durand JB, Gibbs H,
`Zafarmand AA, Ewer MS: Cardiovascular
`complications of cancer therapy: Diagnosis,
`pathogenesis, and management. Circulation
`2004;109:3122-3131.
`17 Gill PS, Espina BM, Muggia F, Cabriales S,
`Tulpule A, Esplin JA, Liebman HA, Forssen E,
`Ross ME, Levine AM: Phase I/II clinical and
`pharmacokinetic evaluation of liposomal dau-
`norubicin. J Clin Oncol 1995;13:996—1003.
`
`Chemotherapy for Gastro-Enteropancreatic
`Endocrine Tumours
`
`Neuroendocrinology 2004;80(suppl 1):79-84
`
`83
`
`Pharm.
`ibit 1063
`
`age 005
`
`West-Ward Pharm.
`Exhibit 1063
`Page 005
`
`

`

`18
`
`20
`
`21
`
`22
`
`23
`
`Levine AM, Tulpule A, Espina B, Sherrod A,
`Boswell WD, Lieberman RD, Nathwani BN,
`Welles L: Liposome-encapsulated doxorubicin
`in combination with standard agents (cyclo-
`phospharnide, vincristine, prednisone) in pa-
`tients with newly diagnosed AIDS-related non-
`Hodgkin’s lymphoma: Results of therapy and
`correlates of response. J Clin Oncol 2004;22:
`2662-2670.
`Moertel CG, Hanley JA: Combination chemo-
`therapy trials in metastatic carcinoid tumor
`and the malignant carcinoid syndrome. Cancer
`Clin Trials 1979;2:327-334.
`Engstrom PF, Lavin PT, Moertel CG, Folsch E,
`Douglass HO Jr: Streptozocin plus fluorouracil
`versus doxorubicin therapy for metastatic car-
`cinoid tumor. J Clin Oncol 1984;2:1255—
`1259.
`Moertel CG, O’Conne11 MJ, Reitemeier RJ,
`Rubin J: Evaluation of combined cyclophos-
`phamide and methotrexate therapy in the treat-
`ment of metastatic carcinoid tumor and the
`malignant carcinoid syndrome. Cancer Treat
`Rep 1984;68:665-667.
`Moertel CG, Kvols LK, O'Connell MJ, Rubin
`J: Treatment of neuroendocrine carcinomas
`with combined etoposide and cisplatin. Evi-
`dence of major therapeutic activity in the ana-
`plastic variants of these neoplasms. Cancer
`1991;68:227-232.
`Di Bartolomeo M, Bajetta E, Bochicchio AM,
`Camaghi C, Somma L, Mazzaferro V, Visini
`M, Gebbia V, Tumolo S, Ballatore P: A phase
`II trial of dacarbazine, fluorouracil and epiru-
`bicin in patients with neuroendocrine tumours.
`A study by the Italian Trials in Medical Onco-
`logy (ITMO) Group. Ann Oncol 1995;6:77—
`79.
`
`24
`
`25
`
`26
`
`27
`
`28
`
`29
`
`30
`
`Frame J, Kelsen D, Kemeny N, Cheng E,
`Niedzwiecki D, Heelan R, Lipperrnann R: A
`phase II trial of streptozotocin and adriamycin
`in advanced APUD tumors. Am J Clin Oncol
`1988;11:490-495.
`Andreyev HJ, Scott-Mackie P, Cunningham D,
`Nicolson V, Norman AR, Badve SS, Iveson A,
`Nicolson MC: Phase II study of continuous
`infusion flnorouracil and interferon alfa-2b in
`the palliation of malignant neuroendocrine tu-
`mors. J Clin Oncol l995;13:l486-1492.
`0’Toole D, Maire F, Ruszniewski P: Ablative
`therapies for liver metastases ofdigestive endo-
`crine tumours. Endocr Relat Cancer 2003;10:
`463-468.
`Krenning EP, Kwekkeboom DJ, Valkema R,
`Pauwels S, Kvols LK, De Jong M: Peptide
`receptor radionuclide therapy. Ann N Y Acad
`Sci 2004; 1014:234-245.
`Seitz J, Perrier H, Giovannini M, Monges G,
`Fourdan O, Barrriére N Viens P: Cancers neu-
`roendocrines anaplasiques avancés: intérét de
`l’association VPI6-CDDP. Bull Cancer 1995;
`82:433-434.
`Mitry E, Baudin E, Ducreux M, Sabourin JC,
`Rufie P, Aparicio T, Lasser P, Elias D, Duvil-
`lard P, Schlumberger M, et al: Treatment of
`poorly differentiated neuroendocrine tumours
`with etoposide and cisplatin. Br J Cancer 1999;
`81:1351-1355.
`Fernandez JA, Robles R, Marin C, Hernandez
`Q, Sanchez Bueno F, Ramirez P, Rodriguez
`JM, Lujan JA, Navalon JC, Parrilla P: Role of
`liver transplantation in the management of
`metastatic neuroendocrine tumors. Transplant
`Proc 2003;35:1832-1833.
`
`31
`
`32
`
`33
`
`34
`
`36
`
`37
`
`Baker J, Schnirer II, Yao JC, Carr K, Ho L,
`Ajani JA: Phase II trial of irinotecan in patients
`with advanced carcinoid tumour. Proc Am Soc
`Clin Oncol 2002;2l:662.
`Ansell SM, Pitot HC, Burch PA, Kvols LK,
`Mahoney MR, Rubin J2 A phase II study of
`high-dose paclitaxel in patients with advanced
`neuroendocrine
`tumors. Cancer 2001;9l:
`1543-1548.
`Carr K, Yao JC, Rashid A, Yeung S-C, Skela-
`ruk J, Baker J, Vaugthey JN, Curley S, Ellis L,
`Ajani JA: A phase II trial of imatinib in pa-
`tients with advanced carcinoid tumour. Proc
`Am Soc Clin Oncol 2003;22:4124.
`Fjallskog ML, Lejonklou MH, Gberg KE,
`Eriksson BK, Janson ET: Expression of molec-
`ular targets for tyrosine kinase receptor antago-
`nists in malignant endocrine pancreatic tu-
`mors. Clin Cancer Res 2003;9:1469—1473.
`Theodossiou C, Fayard N, Anthony L, Sartin
`B: CD-117 expression in carcinoid tumors.
`Proc Am Soc Clin Oncol 2003;22:378.
`Hopfner M, Sutter AP, Gerst B, Zeitz M, Sche-
`rubl H: A novel approach in the treatment of
`neuroendocrine gastrointestinal tumours. Tar-
`geting the epidermal growth factor receptor by
`gefrtinib (ZD1839). Br J Cancer 2003;89:
`1766-1775.
`Bajetta E, Rirnassa L, Camaghi C, Seregni E,
`Ferrari L, Di Bartolomeo M, Regalia E, Cassa-
`ta A, Procopio G, Mariani L: 5-Fluorouracil,
`dacarbazine, and epirubicin in the treatment of
`patients with neuroendocrine tumors. Cancer
`1998;83:372-378.
`
`84
`
`Neuroendocrinology 2004;80(suppl 1):79-84
`
`O’Toole/Hentic/Corcos/Ruszniewski
`
`Pharm.
`ibit 1063
`
`age 006
`
`West-Ward Pharm.
`Exhibit 1063
`Page 006
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket